AU · rank #11 · 2026-07-22
GH
NASDAQ · $20.67B (USD)
The exact numbers the algorithm saw.
| Composite score Z-score blend of all factors below. | 1.517 |
|---|---|
| EPS revisions (30d) Change in consensus EPS estimate over the past 30 days ($/share). | +$0.10 |
| Net revisions (30d) Number of analysts revising upward minus downward. | 2 |
| Insider signal (90d) $78,456 across 1 unique buyers. | 3.000 |
| Analyst upside Consensus target $171.08 | +12.3% |
| Momentum acceleration 3-month minus 12-month momentum. | +15.99% |
| Analyst rating 5 = Strong Buy, 1 = Strong Sell. | 4.70 |
| Gross margin TTM | +64.9% |
| 52w high | $174.08 |
| Market cap (USD) | $20.67B |
The AI research card
Independent qualitative review of each pick before the order is placed. On the rare day the research service is unavailable, the paper book trades on the quant ranking alone and no card appears here.
Summary
Guardant Health is a liquid biopsy and cancer screening company whose three franchises—oncology diagnostics, biopharma/data services, and Shield colorectal cancer screening—delivered 48% revenue growth in Q1 2026 with trailing 12-month revenue exceeding $1 billion.
Rationale
The analyst_upside signal is reinforced by 10 target raises in 30 days, a 4.70/5 analyst rating, 75% revision agreement, and accelerating EPS revisions across 7/30/60/90-day windows, all consistent with a genuine fundamental re-rating driven by Shield's explosive volume ramp and raised full-year guidance rather than mere sentiment rotation.
Material risks
- 1Reimbursement and guideline dependence is the primary thesis-breaker—Shield's volume trajectory relies on continued Medicare fee support and potential ACS guideline inclusion, and an adverse coverage or guideline decision would directly collapse the screening growth narrative underpinning the analyst upgrades.
- 2Sustained free-cash-flow burn of $185–$195M guided for 2026 with breakeven not expected until end-2027 means the company will likely need external capital if Shield adoption or margin improvement slips, creating dilution risk that could cap the upside analysts are pricing in.
AI verdict council
Each pick is reviewed independently by 3 models before any order. 2 of 3 voted to proceed.